FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136385058> ?p ?o ?g. }

• W3136385058 abstract "The widespread distribution of heteroreceptor complexes with allosteric receptor-receptor interactions in the CNS represents a novel integrative molecular mechanism in the plasma membrane of neurons and glial cells. It was proposed that they form the molecular basis for learning and short-and long-term memories. This is also true for drug memories formed during the development of substance use disorders like morphine and cocaine use disorders. In cocaine use disorder it was found that irreversible A2AR-D2R complexes with an allosteric brake on D2R recognition and signaling are formed in increased densities in the ventral enkephalin positive striatal-pallidal GABA antireward neurons. In this perspective article we discuss and propose how an increase in opioid heteroreceptor complexes, containing MOR-DOR, MOR-MOR and MOR-D2R, and their balance with each other and A2AR-D2R complexes in the striatal-pallidal enkephalin positive GABA antireward neurons, may represent markers for development of morphine use disorders. We suggest that increased formation of MOR-DOR complexes takes place in the striatal-pallidal enkephalin positive GABA antireward neurons after chronic morphine treatment in part through recruitment of MOR from the MOR-D2R complexes due to the possibility that MOR upon morphine treatment can develop a higher affinity for DOR. As a result, increased numbers of D2R monomers/homomers in these neurons become free to interact with the A2A receptors found in high densities within such neurons. Increased numbers of A2AR-D2R heteroreceptor complexes are formed and contribute to enhanced firing of these antireward neurons due to loss of inhibitory D2R protomer signaling which finally leads to the development of morphine use disorder. Development of cocaine use disorder may instead be reduced through enkephalin induced activation of the MOR-DOR complex inhibiting the activity of the enkephalin positive GABA antireward neurons. Altogether, we propose that these altered complexes could be pharmacological targets to modulate the reward and the development of substance use disorders." @default.
• W3136385058 created "2021-03-29" @default.
• W3136385058 creator A5016373261 @default.
• W3136385058 creator A5017233022 @default.
• W3136385058 creator A5019645561 @default.
• W3136385058 creator A5036593459 @default.
• W3136385058 creator A5040729812 @default.
• W3136385058 creator A5042882153 @default.
• W3136385058 creator A5069780616 @default.
• W3136385058 creator A5074323215 @default.
• W3136385058 creator A5078169923 @default.
• W3136385058 creator A5078279290 @default.
• W3136385058 creator A5080357111 @default.
• W3136385058 creator A5086684669 @default.
• W3136385058 creator A5089406761 @default.
• W3136385058 creator A5089838749 @default.
• W3136385058 date "2021-03-15" @default.
• W3136385058 modified "2023-10-03" @default.
• W3136385058 title "The Balance of MU-Opioid, Dopamine D2 and Adenosine A2A Heteroreceptor Complexes in the Ventral Striatal-Pallidal GABA Antireward Neurons May Have a Significant Role in Morphine and Cocaine Use Disorders" @default.
• W3136385058 cites W1481198769 @default.
• W3136385058 cites W1528453294 @default.
• W3136385058 cites W1636386427 @default.
• W3136385058 cites W173323332 @default.
• W3136385058 cites W1767831672 @default.
• W3136385058 cites W1818669978 @default.
• W3136385058 cites W1965565628 @default.
• W3136385058 cites W1971256251 @default.
• W3136385058 cites W1973299121 @default.
• W3136385058 cites W1978267269 @default.
• W3136385058 cites W1979747061 @default.
• W3136385058 cites W1994327324 @default.
• W3136385058 cites W2002369190 @default.
• W3136385058 cites W2002515575 @default.
• W3136385058 cites W2007355246 @default.
• W3136385058 cites W2012630232 @default.
• W3136385058 cites W2027591014 @default.
• W3136385058 cites W2029192439 @default.
• W3136385058 cites W2030652795 @default.
• W3136385058 cites W2035235513 @default.
• W3136385058 cites W2035967600 @default.
• W3136385058 cites W2040799021 @default.
• W3136385058 cites W2049277272 @default.
• W3136385058 cites W2064715357 @default.
• W3136385058 cites W2066729230 @default.
• W3136385058 cites W2088672500 @default.
• W3136385058 cites W2096686163 @default.
• W3136385058 cites W2096688894 @default.
• W3136385058 cites W2098885564 @default.
• W3136385058 cites W2112698036 @default.
• W3136385058 cites W2129530731 @default.
• W3136385058 cites W2138997609 @default.
• W3136385058 cites W2140257707 @default.
• W3136385058 cites W218056410 @default.
• W3136385058 cites W2302471419 @default.
• W3136385058 cites W2326575999 @default.
• W3136385058 cites W2466169662 @default.
• W3136385058 cites W2497275630 @default.
• W3136385058 cites W2557290778 @default.
• W3136385058 cites W2563301253 @default.
• W3136385058 cites W2584321011 @default.
• W3136385058 cites W2589970381 @default.
• W3136385058 cites W2593204000 @default.
• W3136385058 cites W2771316861 @default.
• W3136385058 cites W2793853342 @default.
• W3136385058 cites W2800201684 @default.
• W3136385058 cites W2895280172 @default.
• W3136385058 cites W2898699929 @default.
• W3136385058 cites W2909769799 @default.
• W3136385058 cites W2967526936 @default.
• W3136385058 cites W2991006743 @default.
• W3136385058 cites W3000234111 @default.
• W3136385058 cites W3018580114 @default.
• W3136385058 cites W3032205766 @default.
• W3136385058 cites W3034718462 @default.
• W3136385058 cites W3036660506 @default.
• W3136385058 cites W3044005127 @default.
• W3136385058 cites W4237664212 @default.
• W3136385058 cites W4243812700 @default.
• W3136385058 cites W4252911236 @default.
• W3136385058 cites W4297627420 @default.
• W3136385058 doi "https://doi.org/10.3389/fphar.2021.627032" @default.
• W3136385058 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8005530" @default.
• W3136385058 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33790790" @default.
• W3136385058 hasPublicationYear "2021" @default.
• W3136385058 type Work @default.
• W3136385058 sameAs 3136385058 @default.
• W3136385058 citedByCount "7" @default.
• W3136385058 countsByYear W31363850582021 @default.
• W3136385058 countsByYear W31363850582022 @default.
• W3136385058 countsByYear W31363850582023 @default.
• W3136385058 crossrefType "journal-article" @default.
• W3136385058 hasAuthorship W3136385058A5016373261 @default.
• W3136385058 hasAuthorship W3136385058A5017233022 @default.
• W3136385058 hasAuthorship W3136385058A5019645561 @default.
• W3136385058 hasAuthorship W3136385058A5036593459 @default.
• W3136385058 hasAuthorship W3136385058A5040729812 @default.
• W3136385058 hasAuthorship W3136385058A5042882153 @default.
• W3136385058 hasAuthorship W3136385058A5069780616 @default.
• W3136385058 hasAuthorship W3136385058A5074323215 @default.
• W3136385058 hasAuthorship W3136385058A5078169923 @default.

• next